Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Canadian Ticagrelor Survey

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by AstraZeneca
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01757483
First received: December 18, 2012
Last updated: October 29, 2014
Last verified: October 2014
  Purpose

This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns (i.e., bleeding, dyspnea and drug interactions) and ASA dosage.


Condition
Acute Coronary Syndrome

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Effectiveness of Risk Minimisation Interventions for Ticagrelor in Canada

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • KAU Questionnaire: Knowledge of the 4 key safety issues pertaining to ticagrelor (adequate or inadequate for each safety issue) [ Time Frame: 2 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • KAU Questionnaire: Practice characteristics [ Time Frame: 2 months ] [ Designated as safety issue: No ]
  • KAU Questionnaire: The difference in knowledge of understanding across the key safety concerns [ Time Frame: 2 months ] [ Designated as safety issue: No ]
  • KAU Questionnaire: Association between prescribers' characteristics and knowledge and understanding of the key safety concerns. [ Time Frame: 2 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: November 2012
Estimated Study Completion Date: February 2015
Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts
Prescribers

Detailed Description:

Effectiveness of risk minimisation interventions for ticagrelor in Canada

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

All physicians who have prescribed at least one dose of ticargrelor and complete the Knowledge and understanding survey

Criteria

Inclusion Criteria:

- N/A (All prescribers will be contacted for participation)

Exclusion Criteria:

- Participation in a previous wave of the survey.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01757483

Contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com

Locations
Canada, Quebec
Research Site Recruiting
Montreal, Quebec, Canada
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Yola Moride, PhD Université de Montréal
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01757483     History of Changes
Other Study ID Numbers: D5130L00009
Study First Received: December 18, 2012
Last Updated: October 29, 2014
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Acute Coronary Syndrome
Angina Pectoris
Cardiovascular Diseases
Chest Pain
Heart Diseases
Myocardial Ischemia
Pain
Signs and Symptoms
Vascular Diseases

ClinicalTrials.gov processed this record on November 25, 2014